Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: A pooled analysis of three randomized trials

Anti-Cancer Drugs

Volumn 22, Issue 10, 2011, Pages 1010-1019

  Petrelli, Fausto ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

erlotinib; first line chemotherapy; maintenance therapy; non small cell lung cancer; progression free survival

Indexed keywords

BEVACIZUMAB; ERLOTINIB; GEMCITABINE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 80053646484     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328349d80d     Document Type: Article

References (15)

1. Azzoli CG, Giaccone G, Temin S. American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract 2010; 6:39-43.
2. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, doubleblind, phase 3 study. Lancet 2009; 374:1432-1440.
3. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczé sna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521-529.
4. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591-598.
5. Miller VA, O'Connor P, Soh C, Kabbinavar F, for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Program and abstracts of the 2009 Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, Florida. Abstract LBA8002.
6. Kabbinavar FF, Miller VA, Johnson BE, O'Connor PG, Soh CATLAS Investigators. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Program and abstracts of the 2010 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2010; Chicago, Illinois. Abstract 7526.
7. Perol M, Chouaid C, Milleron BJ, Gervais R, Barlesi F, Westeel V, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. Program and abstracts of the 2010 Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2010; Chicago, Illinois. Abstract 7507.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. (Pubitemid 17189972)
9. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127:820-826. (Pubitemid 27465551)
10. Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 2009; 4:994-1001.
11. Mok TS, Wu Y-L, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
12. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7:389-394. (Pubitemid 44043548)
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132. (Pubitemid 41058344)
14. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20:1335-1343. (Pubitemid 34182817)
15. Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010; 5:1263-1272.